Enovis Corporation (ENOV)

NYSE: ENOV · IEX Real-Time Price · USD
55.67
-0.81 (-1.43%)
Jun 29, 2022 4:01 PM EDT - Market closed

Company Description

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger.

Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand.

The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Enovis Corporation
Country United States
Founded 1995
IPO Date May 8, 2008
Industry Specialty Industrial Machinery
Sector Industrials
Employees 16,200
CEO Matthew Trerotola

Contact Details

Address:
420 National Business Pkwy Fl 5
Annapolis Junction, Maryland 20701-1079
United States
Phone 302 252 9190
Website colfaxcorp.com

Stock Details

Ticker Symbol ENOV
Exchange NYSE
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001420800
ISIN Number US1940145022
SIC Code 3561

Key Executives

Name Position
Mitchell P. Rales Co-Founder and Independent Chairman
Matthew L. Trerotola Chief Executive Officer and Director
Brady R. Shirley President, Chief Operating Officer and Director
Christopher M. Hix Executive Vice President of Finance and Chief Financial Officer
Daniel A. Pryor Executive Vice President of Strategy and Business Development
John Kleckner Principal Accounting Officer
Michael S. Macek Vice President of Finance and Investor Relations
Bradley J. Tandy Senior Vice President and General Counsel
Katie Sweet Vice President of Corporate Communication
Patricia A. Lang Senior Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Jun 29, 2022 11-K Annual report of employee stock purchase, savings and similar plans
Jun 13, 2022 8-K Current report
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 4 Statement of changes in beneficial ownership of securities